Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously reported that prostaglandin (PG)E1 and PGF2alpha induce the synthesis of
interleukin-6
(
IL-6
) via activation of protein kinase (PK)A and PKC, respectively, in osteoblast-like MC3T3-E1 cells. In addition, we have shown that basic fibroblast growth factor (bFGF) elicits
IL-6
synthesis through intracellular Ca2+ mobilization in these cells and that tumor necrosis factor-alpha (TNF) induces
IL-6
synthesis through sphingosine 1-phosphate produced by sphingomyelin hydrolysis. In the present study, among sphingomyelin metabolites, we examined the effect of sphingosine on
IL-6
synthesis induced by various agonists in MC3T3-E1 cells. Sphingosine inhibited the
IL-6
synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC. Sphingosine suppressed the PGE1-induced
IL-6
synthesis. The
IL-6
synthesis induced by cholera toxin, forskolin, or dibutyryl cAMP was inhibited by sphingosine. Sphingosine inhibited the
IL-6
synthesis induced by bFGF or A23187. However, sphingosine did not affect the
IL-6
synthesis induced by interleukin-1. On the contrary, sphingosine enhanced the TNF-induced
IL-6
synthesis. DL-threo-
Dihydrosphingosine
, an inhibitor of sphingosine kinase, reduced the enhancement by sphingosine as well as the TNF-effect. These results indicate that sphingosine modulates the
IL-6
synthesis stimulated by various agonists in osteoblasts.
...
PMID:Sphingosine modulates interleukin-6 synthesis in osteoblasts. 970 71